Ipsilateral silent period: A marker of callosal conduction abnormality in early relapsing-remitting multiple sclerosis?

被引:31
|
作者
Jung, Patrick
Beyerle, Astrid
Hurnpich, Marek
Neumann-Haefelin, Tobias
Lanfermann, Heinrich
Ziemann, Ulf
机构
[1] Univ Frankfurt, Dept Neurol, D-60528 Frankfurt, Germany
[2] Univ Frankfurt, Inst Neuroradiol, D-6000 Frankfurt, Germany
关键词
ipsilateral silent period; central motor conduction time; transcranial magnetic stimulation; corpus callosuni; relapsing-remitting multiple sclerosis;
D O I
10.1016/j.jns.2006.08.008
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: The corpus callosum (CC) is commonly affected in multiple sclerosis (MS). The ipsilateral silent period (iSP) is a putative electrophysiological marker of callosal demyelination. The purpose of this study was to re-assess, under recently established optimised protocol conditions [Jung P., Ziemann U. Differences of the ipsilateral silent period in small hand muscles. Muscle Nerve in press.], its diagnostic sensitivity in MS, about which conflicting results were reported in previous studies. Methods: ISP measurements (onset, duration, and depth) were obtained in the abductor pollicis brevis (APB) muscle of either hand in 49 patients with early relapsing-remitting MS (RRMS) (mean EDSS, 1.3). Standard central motor conduction times to the APB (CMCTAPB) and tibial anterior muscles (CMCTTA), and magnetic resonance images (MRI) were also obtained. Results: ISP measurements showed a similar diagnostic sensitivity (28.6%) as CMCTAPB (24.5%), while diagnostic sensitivities of CMCTTA (69.4%) and MRI of the CC (78.6%) were much higher. Prolongation of iSP duration was the most sensitive single iSP measure. ISP prolongation occurred more frequently when CMCTAPB to the same hand was also prolonged (40.0% vs. 8.4%, p < 0.000 1). The correlation between iSP duration and CMCTAPB was significant (Pearson's r=0.24, p < 0.02), suggesting that iSP duration can be contaminated by demyclination of the contralateral corticospinal tract. ISP duration did not correlate with MRI abnon-nalities of the CC. Conclusions: ISP measures are neither a sensitive nor a specific marker of callosal conduction abnormality in early RRMS. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:133 / 139
页数:7
相关论文
共 50 条
  • [31] Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis
    Rinaldi, F.
    Calabrese, M.
    Seppi, D.
    Puthenparampil, M.
    Perini, P.
    Gallo, P.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1760 - 1767
  • [32] Seasonal variations in exacerbations and MRI parameters in relapsing-remitting multiple sclerosis
    Koziol, JA
    Feng, AC
    NEUROEPIDEMIOLOGY, 2004, 23 (05) : 217 - 223
  • [33] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis
    Muller, Jannis
    Schadelin, Sabine
    Lorscheider, Johannes
    Benkert, Pascal
    Hanni, Peter
    Schmid, Jurg
    Kuhle, Jens
    Derfuss, Tobias
    Granziera, Cristina
    Yaldizli, Ozgur
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (12) : 3809 - 3818
  • [34] Intracortical excitability in patients with relapsing-remitting and secondary progressive multiple sclerosis
    Conte, A.
    Lenzi, D.
    Frasca, V.
    Gilio, F.
    Giacomelli, E.
    Gabriele, M.
    Bettolo, C. Marini
    Iacovelli, E.
    Pantano, P.
    Pozzilli, C.
    Inghilleri, M.
    JOURNAL OF NEUROLOGY, 2009, 256 (06) : 933 - 938
  • [35] In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
    Fianne L. P. Sips
    Francesco Pappalardo
    Giulia Russo
    Roberta Bursi
    BMC Medical Informatics and Decision Making, 22
  • [36] Glatiramer acetate - A review of its use in relapsing-remitting multiple sclerosis
    Simpson, D
    Noble, S
    Perry, C
    CNS DRUGS, 2002, 16 (12) : 825 - 850
  • [37] Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis
    Prakash, R. S.
    Snook, E. M.
    Lewis, J. M.
    Motl, R. W.
    Kramer, A. F.
    MULTIPLE SCLEROSIS JOURNAL, 2008, 14 (09) : 1250 - 1261
  • [38] In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
    Sips, Fianne L. P.
    Pappalardo, Francesco
    Russo, Giulia
    Bursi, Roberta
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2022, 22 (SUPPL 6)
  • [39] Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice
    Alcala-Vicente, Carmen
    Perez-Miralles, Francisco C.
    Gascon-Gimenez, Francisco
    Bosca-Blasco, Isabel
    Navarre-Gimeno, Arantxa
    Coret-Ferrer, Francisco
    Casanova-Estruch, Bonaventura
    REVISTA DE NEUROLOGIA, 2017, 64 (10) : 445 - 453
  • [40] Neuropsychological rehabilitation in patients with relapsing-remitting multiple sclerosis: a systematic review
    Redero, Daniel
    Lazaro, Esther
    Vazquez, Natalia
    Soria, Cristina
    APPLIED NEUROPSYCHOLOGY-ADULT, 2023,